secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ginkgo Bioworks Holdings, Inc. (DNA)
CIK:        0001830214
Form:       8-K
Filed at:   2023-03-01T23:59:59+00:00
Accession:  0000950170-23-005511
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ginkgo Bioworks reports 2022 revenue up 52% to $478M; guides 2023 total revenue at least $275M
--------------------------------------------------------------------------------

- Full year 2022 total revenue $478M (+52% YoY); Foundry $144M (+27%), Biosecurity $334M (+66%).
- Adjusted EBITDA loss widened to $(173)M in 2022 from $(106)M in 2021; operating loss $(2.2)B includes $1.9B stock comp.
- 2023 guidance: 100 new Cell Programs; total revenue at least $275M (Foundry ≥$175M, Biosecurity ≥$100M).
- Cash and equivalents over $1.3B; filing extension for 10-K due to becoming large accelerated filer.
- Added 59 new Cell Programs in 2022 (90% growth); downstream milestone potential added over $2.0B.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1830214/000095017023005511/0000950170-23-005511-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1830214/000095017023005511/dna-20230301.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-005511

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer